Emmaus Life Sciences, Inc.
Emmaus Life Sciences, Inc.
Your view on EMMA
Overview
What the company does, where it operates, and who runs it.
About Emmaus Life Sciences, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Willis C. Lee
- Headquarters
- 21250 Hawthorne Boulevard, Torrance, CA, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Willis C. Lee
- Headquarters
- 21250 Hawthorne Boulevard, Torrance, CA, US
Emmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally.
The company's lead candidate is Endari, an L-glutamine oral powder to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older. It has a collaboration agreement with Kainos Medicine, Inc. for the preclinical development of Kainos' patented IRAK4 inhibitor (KM10544) as an anti-cancer drug.
The company was formerly known as Emmaus Holdings, Inc. and changed its name to Emmaus Life Sciences, Inc. in September 2011. Emmaus Life Sciences, Inc. was founded in 2000 and is headquartered in Torrance, California.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Emmaus Life Sciences, Inc., and the rating behind it. EMMA last traded at $0.01; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Emmaus Life Sciences, Inc.. Starting points for Emmaus Life Sciences, Inc.: EPS -$0.09, beta 9.65 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Emmaus Life Sciences, Inc.. Emmaus Life Sciences, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Emmaus Life Sciences, Inc.. Trailing twelve-month EPS for Emmaus Life Sciences, Inc. stands at -$0.09. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Emmaus Life Sciences, Inc.. Emmaus Life Sciences, Inc. has reported as a listed company since 2000. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Emmaus Life Sciences, Inc. valued side by side against its closest peers. Emmaus Life Sciences, Inc. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Emmaus Life Sciences, Inc., and how their positions are changing. At a $894,118 market value, institutional positions materially move Emmaus Life Sciences, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Emmaus Life Sciences, Inc. executives and directors. Shares of Emmaus Life Sciences, Inc. have traded between $0.0080 and $0.04 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Emmaus Life Sciences, Inc.. Emmaus Life Sciences, Inc. is a $894,118 Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Emmaus Life Sciences, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Emmaus Life Sciences, Inc.. Coverage tracks Emmaus Life Sciences, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.